Coherus Oncology (CHRS) Net Equity Issued and Repurchased (2014 - 2026)

Coherus Oncology (CHRS) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $53.6 million in Q1 2026.

• For the quarter ending Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $53.6 million; the trailing twelve-month figure through Mar 2026 stood at $53.6 million (changed N/A YoY), and the FY2024 full-year result was $1.5 million, down 97.29% from the prior year.
• Net Equity Issued and Repurchased climbed to $53.6 million in Q1 2026, from -$52000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $53.6 million in Q1 2026 to a low of -$52000.0 in Q2 2024.
• A 3-year average of $21.7 million and a median of $6.8 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 77.95% in 2024, while the deepest fall reached 100.11% in 2024.
• Tracing CHRS's Net Equity Issued and Repurchased over 3 years: stood at $46.8 million in 2023, then slumped by 100.11% to -$52000.0 in 2024, then surged by 103273.08% to $53.6 million in 2026.
• Business Quant data shows CHRS's Net Equity Issued and Repurchased at $53.6 million in Q1 2026, -$52000.0 in Q2 2024, and $1.5 million in Q1 2024.